SC
VKTX icon

Stephens Consulting’s Viking Therapeutics VKTX Stock Holding History

Stephens Consulting’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.76K Hold
50
– – ﹤0.01% 358
2025
Q3 		$1.31K Hold
50
– – ﹤0.01% 347
2025
Q2 		$1.32K Hold
50
– – ﹤0.01% 591
2025
Q1 		$1.21K Hold
50
– – ﹤0.01% 564
2024
Q4 		$2.01K Buy
+50
New +$2.85K ﹤0.01% 463

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Stephens Consulting's VKTX Position: Q4 2025 in Review

Stephens Consulting held its Viking Therapeutics (VKTX) position steady in Q4 2025 at 50 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #358.

Stephens Consulting first reported a position in VKTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.01K in Q4 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Stephens Consulting held 50 shares of Viking Therapeutics worth $1.76K as of Q4 2025.
  • Stephens Consulting left its Viking Therapeutics share count unchanged in Q4 2025.
  • Viking Therapeutics made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #358 holding.
  • Stephens Consulting first reported a position in Viking Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Stephens Consulting's Viking Therapeutics position peaked at $2.01K in Q4 2024.
  • 426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.